Security key
90466Y202
Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (UNCY)
CUSIP: 90466Y202
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 28,293,758
- Total 13F shares
- 5,144,083
- Share change
- +5,144,083
- Total reported value
- $24,616,897
- Price per share
- $4.77
- Number of holders
- 19
- Value change
- +$24,616,897
- Number of buys
- 19
Report period
Q2 2025
Institutions
19
Top holders
10
UNCY full security history
Newer quarter: Q3 2025
Unicycive Therapeutics, Inc. SEC filings
Unicycive Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 90466Y202
Recent filing periods:
Top shareholders of UNCY - Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
— |
10%
|
60,961,729
|
$38,405,889 | $0 | 31 Mar 2025 | |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
|
BVF PARTNERS L P/IL |
10%
|
1,417,117
|
$7,439,864 | $0 | 30 Jun 2025 | |
| GREAT POINT PARTNERS LLC |
13D/G
13F
|
Company |
10%
|
11,473,166
|
$7,228,095 | $0 | 31 Dec 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
— |
9.9%
|
13,285,781
|
$8,370,042 | +$1,112,366 | 31 Mar 2025 | |
| Walleye Capital LLC |
13D/G
13F
|
Company |
4.8%
|
5,000,000
|
$3,150,000 | $0 | 31 Dec 2024 | |
| Nantahala Capital Partners Limited Partnership |
13D/G
|
— |
2.8%
|
3,009,021
|
$1,895,683 | -$3,073,653 | 19 Dec 2024 | |
| Vivo Capital, LLC |
13F
|
Company |
61%
|
11,370,152
|
$6,536,700 | — | 31 Mar 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
54%
|
10,000,000
|
$5,749,000 | — | 31 Mar 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
51%
|
9,391,994
|
$5,399,457 | — | 31 Mar 2025 | |
| Logos Global Management LP |
13F
|
Company |
27%
|
5,078,927
|
$2,919,875 | — | 31 Mar 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
13%
|
2,413,489
|
$1,387,515 | — | 31 Mar 2025 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
13%
|
2,352,887
|
$1,352,675 | — | 31 Mar 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
9.4%
|
1,750,000
|
$1,006,075 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
6.5%
|
1,212,441
|
$697,154 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.1%
|
579,202
|
$332,982 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.67%
|
125,236
|
$71,998 | — | 31 Mar 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.66%
|
123,233
|
$70,847 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.58%
|
107,850
|
$62,003 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.45%
|
83,242
|
$47,856 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.4%
|
73,475
|
$42,241 | — | 31 Mar 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.21%
|
38,868
|
$22,000 | — | 31 Mar 2025 | |
| CANTOR FITZGERALD, L. P. |
13F
|
Individual |
0.18%
|
32,971
|
$18,955 | — | 31 Mar 2025 | |
| Creative Planning |
13F
|
Company |
0.14%
|
25,910
|
$14,896 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.12%
|
22,266
|
$12,801 | — | 31 Mar 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.1%
|
17,816
|
$10,000 | — | 31 Mar 2025 | |
| TANDEM CAPITAL MANAGEMENT CORP /ADV |
13F
|
Company |
0.08%
|
15,500
|
$8,911 | — | 31 Mar 2025 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.08%
|
14,840
|
$8,532 | — | 31 Mar 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.06%
|
12,044
|
$6,924 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.05%
|
9,552
|
$5,492 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
428
|
$246 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
184
|
$106 | — | 31 Mar 2025 | |
| Bogart Wealth, LLC |
13F
|
Company |
0%
|
60
|
$34 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
25
|
$14 | — | 31 Mar 2025 | |
| John L. Ryan |
3/4/5
|
Director |
—
class O/S missing
|
123,775
|
— | — | 05 Sep 2023 | |
| Brigitte Schiller |
3/4/5
|
Director |
—
class O/S missing
|
41,738
|
— | — | 15 Jul 2022 |
Institutional Holders of Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (UNCY) as of Q2 2025
As of 30 Jun 2025,
Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (UNCY) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,144,083 shares.
The largest 10 holders included
Vivo Capital, LLC, Octagon Capital Advisors LP, Nantahala Capital Management, LLC, GREAT POINT PARTNERS LLC, VANGUARD GROUP INC, Logos Global Management LP, ACUTA CAPITAL PARTNERS, LLC, GEODE CAPITAL MANAGEMENT, LLC, JPMORGAN CHASE & CO, and STATE STREET CORP.
This page lists
20
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q4 2025 Across Filers
Q4 2025 holders
34
Q2 2025 holders
19
Holder diff
-15
| Investor | Q4 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.